OBJECTIVE:Disulfiram is a potential cocaine addiction pharmacotherapy. Since dopamine deficiency has been found with cocaine addiction, our objective was to examine whether functional variants in the ankyrin repeat and kinase domain-containing 1 (ANKK1) and/or the dopamine receptor D2 (DRD2) genes interact with response to treatment with disulfiram. MATERIALS AND METHODS:Cocaine and opioid codependent (DSM-IV) patients were stabilized on methadone and subsequently randomized into treatment groups - disulfiram (250 mg/day, N=31) or placebo (N=37). They were genotyped for ANKK1 (rs1800497) and DRD2 (rs2283265) polymorphisms, and the data were evaluated for an association between a cocaine-free state, as assessed by cocaine-free urine samples, and disulfiram treatment. Data were analyzed using repeated measures analysis of variance corrected for population structure. RESULTS: Patients with CT or TT ANKK1 genotypes dropped from 80 to 52% cocaine-positive urines on disulfiram (N=13; P≤0.0001), whereas those on placebo (N=20) showed no treatment effect. Patients carrying the CC ANKK1 genotype showed no effect on treatment with disulfiram (N=18) or placebo (N=17). The GT/TT DRD2 genotype group showed a significant decrease in the number of cocaine-positive urine samples on disulfiram (N=9; 67-48%; P ≤ 0.0001), whereas the GG DRD2 genotype group showed only a marginal decrease (N=23; 84-63%; P=0.04). Genotype pattern analysis revealed that individuals carrying at least one minor allele in either gene responded better to disulfiram treatment (N=13; P ≤ 0.0001) compared with individuals carrying only the major alleles (N=17). CONCLUSION: A patient's genotype for ANKK1, DRD2, or both, may be used to identify individuals for whom disulfiram may be an effective pharmacotherapy for cocaine dependence.
RCT Entities:
OBJECTIVE:Disulfiram is a potential cocaine addiction pharmacotherapy. Since dopamine deficiency has been found with cocaine addiction, our objective was to examine whether functional variants in the ankyrin repeat and kinase domain-containing 1 (ANKK1) and/or the dopamine receptor D2 (DRD2) genes interact with response to treatment with disulfiram. MATERIALS AND METHODS:Cocaine and opioid codependent (DSM-IV) patients were stabilized on methadone and subsequently randomized into treatment groups - disulfiram (250 mg/day, N=31) or placebo (N=37). They were genotyped for ANKK1 (rs1800497) and DRD2 (rs2283265) polymorphisms, and the data were evaluated for an association between a cocaine-free state, as assessed by cocaine-free urine samples, and disulfiram treatment. Data were analyzed using repeated measures analysis of variance corrected for population structure. RESULTS:Patients with CT or TT ANKK1 genotypes dropped from 80 to 52% cocaine-positive urines on disulfiram (N=13; P≤0.0001), whereas those on placebo (N=20) showed no treatment effect. Patients carrying the CC ANKK1 genotype showed no effect on treatment with disulfiram (N=18) or placebo (N=17). The GT/TT DRD2 genotype group showed a significant decrease in the number of cocaine-positive urine samples on disulfiram (N=9; 67-48%; P ≤ 0.0001), whereas the GG DRD2 genotype group showed only a marginal decrease (N=23; 84-63%; P=0.04). Genotype pattern analysis revealed that individuals carrying at least one minor allele in either gene responded better to disulfiram treatment (N=13; P ≤ 0.0001) compared with individuals carrying only the major alleles (N=17). CONCLUSION: A patient's genotype for ANKK1, DRD2, or both, may be used to identify individuals for whom disulfiram may be an effective pharmacotherapy for cocaine dependence.
Authors: E G Jönsson; M M Nöthen; F Grünhage; L Farde; Y Nakashima; P Propping; G C Sedvall Journal: Mol Psychiatry Date: 1999-05 Impact factor: 15.992
Authors: Michael A Nader; Drake Morgan; H Donald Gage; Susan H Nader; Tonya L Calhoun; Nancy Buchheimer; Richard Ehrenkaufer; Robert H Mach Journal: Nat Neurosci Date: 2006-07-09 Impact factor: 24.884
Authors: Robert A Moyer; Danxin Wang; Audrey C Papp; Ryan M Smith; Linda Duque; Deborah C Mash; Wolfgang Sadee Journal: Neuropsychopharmacology Date: 2010-12-08 Impact factor: 7.853
Authors: Shabnam Azadeh; Brian P Hobbs; Liangsuo Ma; David A Nielsen; F Gerard Moeller; Veerabhadran Baladandayuthapani Journal: Neuroimage Date: 2015-10-17 Impact factor: 6.556
Authors: Shirley Y Hill; Bobby L Jones; Stuart R Steinhauer; Nicholas Zezza; Scott Stiffler Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2016-01-12 Impact factor: 3.568
Authors: Michelle A Patriquin; Isabelle E Bauer; Jair C Soares; David P Graham; David A Nielsen Journal: Psychiatr Genet Date: 2015-10 Impact factor: 2.458
Authors: June P Kampangkaew; Catherine J Spellicy; Ellen M Nielsen; Mark J Harding; An Ye; Sara C Hamon; Thomas R Kosten; David A Nielsen Journal: Am J Addict Date: 2019-05-14
Authors: Anderson R Stolf; Renata B Cupertino; Diana Müller; Breno Sanvicente-Vieira; Tatiana Roman; Eduardo S Vitola; Eugenio H Grevet; Lisia von Diemen; Felix H P Kessler; Rodrigo Grassi-Oliveira; Claiton H D Bau; Diego L Rovaris; Flavio Pechansky; Jaqueline B Schuch Journal: J Neural Transm (Vienna) Date: 2018-10-26 Impact factor: 3.575
Authors: Steven Kushner; David Han; Marlene Oscar-Berman; B William Downs; Margaret A Madigan; John Giordano; Thomas Beley; Scott Jones; Debmayla Barh; Thomas Simpatico; Kristina Dushaj; Raquel Lohmann; Eric R Braverman; Stephen Schoenthaler; David Ellison; Kenneth Blum Journal: J Addict Res Ther Date: 2013-07-02
Authors: Bao-Zhu Yang; Iris M Balodis; Hedy Kober; Patrick D Worhunsky; Cheryl M Lacadie; Joel Gelernter; Marc N Potenza Journal: Addict Behav Date: 2020-10-10 Impact factor: 3.913